Welcome to our dedicated page for DermTech news (Ticker: DMTK), a resource for investors and traders seeking the latest updates and insights on DermTech stock.
DermTech, Inc. (symbol: DMTK) is a groundbreaking molecular diagnostic dermatology company dedicated to revolutionizing the diagnosis of skin conditions through innovative non-invasive testing. Located at their CLIA-licensed laboratory in La Jolla, CA, DermTech operates at the cutting edge of dermatological science.
DermTech's core technology focuses on gene expression tests that aid in the clinical diagnosis of skin cancer and other skin conditions. Their flagship product, the Pigmented Lesion Assay (PLA), allows for the analysis of skin biopsy samples using an adhesive patch. This method offers a significant advancement over traditional methods that rely on subjective visual diagnosis and invasive surgical biopsies, which are often prone to error and lead to unnecessary procedures.
The PLA test is designed to detect melanoma in clinically atypical pigmented lesions with high accuracy, providing physicians with critical, objective data to enhance patient care and reduce healthcare costs. By utilizing DermTech’s non-invasive approach, patients experience enhanced comfort and safety during the diagnostic process.
DermTech is committed to advancing the field of dermatology through continuous innovation. In addition to their focus on skin cancer, the company is developing genomic tests to diagnose inflammatory skin diseases and conditions related to aging. These efforts are aimed at providing comprehensive solutions that improve the accuracy of diagnoses and overall patient outcomes.
With a strong emphasis on scientific development and patient care, DermTech partners with various healthcare providers and institutions to expand the availability of their tests. The company generates revenue through their laboratory services, ensuring a sustainable business model while aiming for growth and expanded impact in the dermatology field.
DermTech (NASDAQ: DMTK) has announced that a significant study published in SKIN: The Journal of Cutaneous Medicine demonstrates the efficacy of its Pigmented Lesion Assay (PLA) in improving melanoma diagnostics. The TRUST study, involving 2,575 lesions, reveals the PLA achieves a negative predictive value (NPV) exceeding 99% and a real-world positive predictive value (PPV) of 18.7%. This approach reduces unnecessary biopsies while enhancing melanoma detection, showcasing DermTech's innovative contributions to precision dermatology.
DermTech, Inc. (NASDAQ: DMTK) has announced its upcoming presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 4:35 p.m. ET. The live webcast will be accessible through the Investor Relations section of DermTech's website, with an archived version available for 90 days post-event. DermTech is pioneering precision dermatology using a non-invasive skin genomics platform aimed at early skin cancer detection and treatment customization. For further information, visit DermTech.com.
DermTech (NASDAQ: DMTK) will present its DermTech Melanoma Test at the 2021 Florida Association of Health Plans annual conference from November 14-16. The Chief Medical Officer, Dr. Loren Clarke, will discuss the benefits of early melanoma detection through genomic analysis. Notably, Florida sees about 10% of U.S. melanoma cases annually. DermTech aims to enhance patient care and economic outcomes with its non-invasive testing approach, having recently joined FAHP as an associate member in August 2021.
DermTech (NASDAQ: DMTK) announced its participation in the Lake Street 2021 BIG5 Conference on September 14, 2021. As a leader in precision dermatology, DermTech utilizes a non-invasive skin genomics platform aimed at early cancer detection and customized treatments for inflammatory diseases. Their mission is to democratize dermatology care and enhance patient outcomes through innovative genomic analysis. For more information, visit www.DermTech.com.
DermTech (NASDAQ: DMTK) reported impressive financial results for Q2 2021, showcasing a 269% year-over-year increase in total revenue to $3.1 million, driven by a 267% rise in billable sample volume. Assay revenue surged 349% to $2.9 million. The company achieved a positive assay gross margin of 11%, compared to negative margins in 2020. Cash and equivalents stood at $268.3 million. DermTech also launched PLAplus for improved melanoma detection and provided updated revenue guidance of $11.5 million to $13.5 million for the full year, indicating strong growth prospects.
DermTech, Inc. (NASDAQ: DMTK) will release its Q2 2021 financial results on August 4, 2021, after market close. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET that same day, where the company will discuss financial outcomes and recent highlights. Interested participants can join via phone or through a live webinar accessible on DermTech's investor website. DermTech is a leader in precision dermatology using non-invasive skin genomics, focusing on early skin cancer detection and customized drug treatments.
DermTech (NASDAQ: DMTK) announced plans to expand its operations in San Diego by leasing a 96,000 square-foot facility from Kilroy Realty. This new headquarters will house the DermTech Gene Lab, enabling enhanced capacity for processing the DermTech Melanoma Test, crucial for early melanoma detection. The building transformation includes converting 30,000 square feet to laboratory space, with an expected multi-phase opening starting soon. The lease spans 126 months with options for extensions. This expansion reflects DermTech's strategy to capture market opportunities in the growing biotech field.
DermTech (NASDAQ: DMTK) has appointed Monica Tellado, former Senior VP of Finance at Gilead Sciences, to its Board of Directors. This move is seen as beneficial for DermTech's growth strategy, as Tellado brings extensive experience in commercializing products and operational excellence. With 18 years at Gilead, she led market entry strategies and managed significant business units, including a $2 billion Liver Disease division. Tellado aims to advance DermTech’s mission of revolutionizing skin health through genomics, marking a pivotal point in the company’s growth trajectory.
DermTech (NASDAQ: DMTK) has announced a collaboration with researchers from the University of Barcelona to explore targeted therapies for inflammatory skin diseases like atopic dermatitis and psoriasis. This study utilizes DermTech’s Smart StickerTM platform to examine inflammatory pathways. With significant prevalence in both children and adults, these conditions incur substantial social and economic costs. The partnership aims to enhance the understanding of these diseases and the effectiveness of personalized treatments, reflecting DermTech's commitment to precision dermatology.
FAQ
What is the current stock price of DermTech (DMTK)?
What is the market cap of DermTech (DMTK)?
What does DermTech, Inc. specialize in?
How does DermTech's Pigmented Lesion Assay (PLA) work?
Where is DermTech, Inc. located?
What makes DermTech's diagnostic method unique?
What other skin conditions does DermTech focus on?
How does DermTech improve patient care?
Is DermTech's technology widely available?
How does DermTech generate revenue?
What is DermTech's mission?
What recent achievements has DermTech made?
